Welcome to our dedicated page for Q BIOMED news (Ticker: QBIO), a resource for investors and traders seeking the latest updates and insights on Q BIOMED stock.
Q BioMed Inc. (OTCQB: QBIO) is a cutting-edge biomedical acceleration and development company based in New York, New York. Established in 2013 and formerly known as ISMO Tech Solutions, Inc., Q BioMed has positioned itself as a vital player in the life sciences and healthcare sectors.
The company's principal focus is on licensing, acquiring, and providing resources to various healthcare and life sciences enterprises. Among its core products is Strontium Chloride Sr89, a radiopharmaceutical therapeutic designed to alleviate bone cancer pain. Additionally, Metastron, another radiopharmaceutical, offers therapeutic solutions for metastatic cancer bone pain. Q BioMed is also pioneering several other significant projects, including MAN-01, a pre-clinical candidate targeting primary open-angle glaucoma; QBM-001, aimed at treating rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, developed for liver cancer treatment.
A noteworthy partnership with Mannin Research underscores Q BioMed's commitment to innovation, collaborating on the development of novel treatments for COVID-19. The company’s strategy emphasizes not only acquiring undervalued biomedical assets but also providing these assets with the critical resources, developmental support, and capital necessary for reaching their full potential.
Q BioMed is currently navigating some financial challenges. According to a recent update, the company was unable to file complete audited financials for 2022 due to capital constraints and the costs involved in the audit process. This led to a downgrade to the 'Expert Market' segment of the OTC. Despite these challenges, Q BioMed is actively engaging with consultants and bankers to restructure its funding and potentially relist on the market or pursue mergers and acquisitions with compatible entities.
Q BioMed remains steadfast in its mission to unlock shareholder value and continues to explore various options for financial restructuring. The company is dedicated to providing regular updates to its shareholders and ensuring transparency throughout this process.
Q BioMed Inc. (OTCQB: QBIO) outlines its strategic goals for 2022, focusing on monetizing its biotech asset pipeline. Key initiatives include revenue growth from Strontium89, partnerships for UTTROSIDE B in liver cancer, and enhancing joint ventures, particularly with the Mannin Platform targeting ARDS and other serious conditions. The company aims to transition to Nasdaq while emphasizing its commitment to rare diseases. With potential multi-billion dollar markets, Q BioMed highlights its need for capital to advance these initiatives and deliver value to shareholders.
Q BioMed Inc. (OTCQB: QBIO) reported a remarkable year-over-year revenue increase exceeding 600% and a 100% rise in Q4 compared to Q3. This growth is attributed to the Strontium89 commercial program, gaining Medicare and Medicaid reimbursements, and a partnership with Eversana for institutional sales. The firm is also advancing its drug development pipeline, including therapies for Acute Respiratory Distress Syndrome and liver cancer, and preparing for a Nasdaq uplisting in January 2022. These developments signal promising market potential for shareholders.
Q BioMed Inc. (OTCQB: QBIO) announced a partnership with EVERSANA to enhance the commercialization of Strontium89, an FDA-approved treatment for metastatic cancer bone pain. This collaboration aims to leverage EVERSANA's comprehensive commercial model which includes market access and analytics to optimize product support. In pivotal trials, Strontium89 demonstrated pain relief in 79% of patients. The commercial rollout will target U.S. Veterans Affairs and Department of Defense sectors, utilizing EVERSANA's experienced workforce.
Q BioMed Inc. (OTCQB: QBIO) announced on October 25, 2021 that it has secured an additional $2 million in funding to support its uplisting and operational needs for the next 12 months. The company notes increased product inquiries for its Strontium-89 as a competitor has ceased production of QUADRAMET®. Upcoming clinical trials for the Mannin platform may unlock over $200 million in potential licensing revenues across various medical indications. They are also focused on expanding their product offerings and plan for a European launch in early 2022.
Q BioMed Inc. (OTCQB: QBIO) announced a significant increase in sales of Strontium89, a treatment for metastatic bone pain, predicting Q4 revenue could double previous figures. The company secured its first order from the VA healthcare system, reflecting growing confidence in the product. CEO Denis Corin noted the positive momentum from repeat orders and collaboration with veterans' services. Strontium89 shows encouraging clinical trial results, with up to 79% of patients experiencing pain relief. The company aims for further growth with strategic funding and market expansion.
Q BioMed Inc. (OTCQB: QBIO) announced an update on its MAN-19 therapeutic, aimed at treating Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. The recombinant fusion protein enhances blood vessel strength and aims to prevent ICU admissions. Early preclinical results are promising, with clinical trials expected to commence in 2022, pending toxicology tests. The company anticipates substantial revenue opportunities, estimating potential milestones worth $200M in the next 24 months. A commitment of $10M has been made towards the Tie2 platform development, enhancing its market positioning.
Q BioMed Inc. (OTCQB: QBIO) has received a patent allowance in South Korea for Uttroside B, complementing existing patents in Canada and Japan. This development, along with promising results from pre-clinical pharmacokinetic tests, positions Uttroside B as a valuable contender in the liver cancer market. There is significant demand for effective treatments, as approximately 42,230 people are diagnosed with primary liver cancer in the U.S. annually. The liver cancer drug market was valued at US$824 million in 2020, with a projected CAGR of 29.4% through 2030.
Q BioMed Inc. (OTCQB: QBIO) has entered an exclusive distribution agreement with isoSolutions Marketing & Management Inc. for the distribution of Strontium89 in Canada, a radiopharmaceutical for treating painful skeletal metastases from cancer. Strontium89 is FDA-approved, providing significant relief in clinical trials, with 79% of patients experiencing pain reduction. Over ten million individuals worldwide could benefit from Strontium89, which has seen limited availability recently. Q BioMed aims to enhance access and awareness while pursuing regulatory approvals in other markets.
Q BioMed Inc. (OTCQB: QBIO) has partnered with WSI PBG, LLC to promote Strontium89 across 76 Veterans Administration and Military Health System medical centers. This collaboration will enhance access to Strontium Chloride Sr-89 Injection, aimed at treating bone pain caused by metastatic cancers, particularly among veterans at higher cancer risk. The treatment has shown significant efficacy, with 79% of patients experiencing pain relief. The partnership aims to increase Strontium89's presence in federal health systems, aligning with Q BioMed's growth strategy.
Q BioMed Inc. (OTCQB: QBIO) has partnered with WSI PBG, LLC to enhance sales of Strontium89 in the U.S. Department of Veterans Affairs and Military Health System. With 6 Federal Account Managers, WSI will promote Strontium89 to 76 medical centers, targeting veterans, who are at increased risk for certain cancers. The partnership follows the approval of a Federal Supply Contract, allowing Q BioMed to address the significant bone pain in cancer patients. Clinical trials show that 79% of Strontium89 patients experienced pain relief, establishing it as a viable treatment option.
FAQ
What is the market cap of Q BIOMED (QBIO)?
What does Q BioMed Inc. specialize in?
What are some of the key products of Q BioMed Inc.?
What recent financial challenges has Q BioMed Inc. faced?
What is Q BioMed Inc. doing to address its financial challenges?
Who is Q BioMed Inc. partnering with for COVID-19 therapeutics?
When was Q BioMed Inc. founded?
Where is Q BioMed Inc. headquartered?
What was Q BioMed Inc.'s previous name?
How does Q BioMed Inc. support its acquired assets?
How can shareholders stay updated on Q BioMed Inc.'s developments?
